Global Oncogene-Targeted Drugs Market Growth (Status and Outlook) 2026-2032
The global Oncogene-Targeted Drugs market size is predicted to grow from US$ 63177 million in 2025 to US$ 106464 million in 2032; it is expected to grow at a CAGR of 7.8% from 2026 to 2032.
Oncogene-Targeted Drugs are antineoplastic medicines designed to act on oncogenic driver alterations and their encoded proteins, receptors, or downstream signaling pathways that play a critical role in tumor initiation, maintenance, and progression. They include small-molecule targeted agents and biologic products; the former are commonly formulated as tablets, capsules, or injectables, whereas the latter are typically injectable monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates. Their composition generally consists of an active pharmaceutical ingredient, excipients, and a suitable dosage-form system, and some products are used together with companion diagnostics. By selectively inhibiting abnormalities involving EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 and related drivers, these drugs block signaling required for cancer-cell proliferation, survival, angiogenesis, or metastasis, thereby improving therapeutic precision and reducing nonselective damage to normal tissues. They are widely used in molecularly defined solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma, as well as selected hematologic malignancies.
The industry position of Oncogene-Targeted Drugs is evolving from a specialized category within oncology therapeutics into a core value node of the precision medicine ecosystem. The primary opportunity comes from the ongoing shift in cancer care from tumor-type-based treatment to molecularly stratified treatment. An increasing number of clinical decisions are now built around the identification of driver alterations such as EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, and HER2, which means these drugs are no longer merely therapeutic end products. Instead, they are becoming part of a high-barrier solution set that integrates genomic testing, companion diagnostics, data interpretation, patient stratification, and real-world evidence. The NCI defines targeted therapy as treatment directed at specific changes that help cancer cells grow, spread, and survive, while the FDA recognizes companion diagnostics as essential to the clinical use of multiple oncology targeted therapies. This gives the segment value far beyond product revenue alone, extending into precision-use efficiency, pathway optimization, and stronger health-economic justification. For companies, the most attractive opportunity lies not in a single asset, but in building platform-based portfolios around advantaged targets, resistance management, combination regimens, and global registration strategies. For investors, the long-term appeal of this market lies in its unique combination of innovation intensity, clinically testable value, and commercial scalability. For policymakers, it represents a strategic lever for upgrading advanced biopharma, molecular diagnostics, and standardized oncology management.
At the same time, this market is not expanding in a linear manner. It is a classic high-R&D, high-regulation, high-competition arena where challenges and risks remain substantial. Commercial success is highly dependent on target validity and accurate patient selection; if the truly addressable patient pool proves smaller than expected, or if companion diagnostic penetration lags, market uptake can be materially constrained. Resistance is another structural challenge: early efficacy rarely guarantees durable positioning, and companies must continuously invest in next-generation molecules, combination strategies, and indication expansion or risk being displaced by new mechanisms. The barriers are not confined to discovery either; they extend across CMC, GMP, multi-region regulatory approval, pharmacovigilance, supply resilience, and reimbursement negotiations. This is especially relevant as more complex molecular modalities such as monoclonal antibodies, bispecifics, and ADCs expand within oncology. In this environment, manufacturing consistency, quality control, and global commercial delivery capability are becoming decisive competitive variables. More importantly, as biomarker-driven development becomes an industry norm, competition is shifting from a race to launch toward a race to build evidence loops, clinical consensus, and access advantages. Companies lacking integrated clinical development capability, diagnostic partnership depth, and international market access expertise will find it increasingly difficult to sustain leadership in high-value niches.
On the demand side, future growth is likely to be driven more by structural upgrading than by volume expansion alone. Hospitals and clinicians increasingly expect these therapies not only to improve response rates, but also to support earlier intervention, more precise stratification, longer survival benefit, and more manageable safety profiles. This is pushing usage from late-stage salvage settings toward adjuvant, neoadjuvant, perioperative, and maintenance settings. At the same time, payers and health systems are moving beyond innovation labels and focusing more closely on real-world outcomes, post-resistance treatment pathways, testing accessibility, and total cost of care. As a result, products that are tightly linked with companion diagnostics, supported by clear patient-selection logic, and embedded into standardized treatment pathways will be better positioned to sustain demand. The downstream customer landscape is also broadening. In addition to major cancer centers, regional hospitals, specialist networks, molecular pathology laboratories, and precision medicine service platforms are playing a larger role, prompting drug makers to move beyond conventional academic promotion toward integrated go-to-market models built around therapeutics, diagnostics, education, and patient management. Overall, demand fundamentals for oncogene-targeted drugs are expected to remain resilient, but the next phase of market deepening will be driven not by conceptual innovation alone, but by system-level solutions capable of balancing molecular diagnostics, therapeutic benefit, accessibility, and commercial reproducibility.
LPI (LP Information)' newest research report, the ?Oncogene-Targeted Drugs Industry Forecast? looks at past sales and reviews total world Oncogene-Targeted Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Oncogene-Targeted Drugs sales for 2026 through 2032. With Oncogene-Targeted Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncogene-Targeted Drugs industry.
This Insight Report provides a comprehensive analysis of the global Oncogene-Targeted Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oncogene-Targeted Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Oncogene-Targeted Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncogene-Targeted Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncogene-Targeted Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncogene-Targeted Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oncogene-Targeted Drugs are antineoplastic medicines designed to act on oncogenic driver alterations and their encoded proteins, receptors, or downstream signaling pathways that play a critical role in tumor initiation, maintenance, and progression. They include small-molecule targeted agents and biologic products; the former are commonly formulated as tablets, capsules, or injectables, whereas the latter are typically injectable monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates. Their composition generally consists of an active pharmaceutical ingredient, excipients, and a suitable dosage-form system, and some products are used together with companion diagnostics. By selectively inhibiting abnormalities involving EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 and related drivers, these drugs block signaling required for cancer-cell proliferation, survival, angiogenesis, or metastasis, thereby improving therapeutic precision and reducing nonselective damage to normal tissues. They are widely used in molecularly defined solid tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, thyroid cancer, and melanoma, as well as selected hematologic malignancies.
The industry position of Oncogene-Targeted Drugs is evolving from a specialized category within oncology therapeutics into a core value node of the precision medicine ecosystem. The primary opportunity comes from the ongoing shift in cancer care from tumor-type-based treatment to molecularly stratified treatment. An increasing number of clinical decisions are now built around the identification of driver alterations such as EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, and HER2, which means these drugs are no longer merely therapeutic end products. Instead, they are becoming part of a high-barrier solution set that integrates genomic testing, companion diagnostics, data interpretation, patient stratification, and real-world evidence. The NCI defines targeted therapy as treatment directed at specific changes that help cancer cells grow, spread, and survive, while the FDA recognizes companion diagnostics as essential to the clinical use of multiple oncology targeted therapies. This gives the segment value far beyond product revenue alone, extending into precision-use efficiency, pathway optimization, and stronger health-economic justification. For companies, the most attractive opportunity lies not in a single asset, but in building platform-based portfolios around advantaged targets, resistance management, combination regimens, and global registration strategies. For investors, the long-term appeal of this market lies in its unique combination of innovation intensity, clinically testable value, and commercial scalability. For policymakers, it represents a strategic lever for upgrading advanced biopharma, molecular diagnostics, and standardized oncology management.
At the same time, this market is not expanding in a linear manner. It is a classic high-R&D, high-regulation, high-competition arena where challenges and risks remain substantial. Commercial success is highly dependent on target validity and accurate patient selection; if the truly addressable patient pool proves smaller than expected, or if companion diagnostic penetration lags, market uptake can be materially constrained. Resistance is another structural challenge: early efficacy rarely guarantees durable positioning, and companies must continuously invest in next-generation molecules, combination strategies, and indication expansion or risk being displaced by new mechanisms. The barriers are not confined to discovery either; they extend across CMC, GMP, multi-region regulatory approval, pharmacovigilance, supply resilience, and reimbursement negotiations. This is especially relevant as more complex molecular modalities such as monoclonal antibodies, bispecifics, and ADCs expand within oncology. In this environment, manufacturing consistency, quality control, and global commercial delivery capability are becoming decisive competitive variables. More importantly, as biomarker-driven development becomes an industry norm, competition is shifting from a race to launch toward a race to build evidence loops, clinical consensus, and access advantages. Companies lacking integrated clinical development capability, diagnostic partnership depth, and international market access expertise will find it increasingly difficult to sustain leadership in high-value niches.
On the demand side, future growth is likely to be driven more by structural upgrading than by volume expansion alone. Hospitals and clinicians increasingly expect these therapies not only to improve response rates, but also to support earlier intervention, more precise stratification, longer survival benefit, and more manageable safety profiles. This is pushing usage from late-stage salvage settings toward adjuvant, neoadjuvant, perioperative, and maintenance settings. At the same time, payers and health systems are moving beyond innovation labels and focusing more closely on real-world outcomes, post-resistance treatment pathways, testing accessibility, and total cost of care. As a result, products that are tightly linked with companion diagnostics, supported by clear patient-selection logic, and embedded into standardized treatment pathways will be better positioned to sustain demand. The downstream customer landscape is also broadening. In addition to major cancer centers, regional hospitals, specialist networks, molecular pathology laboratories, and precision medicine service platforms are playing a larger role, prompting drug makers to move beyond conventional academic promotion toward integrated go-to-market models built around therapeutics, diagnostics, education, and patient management. Overall, demand fundamentals for oncogene-targeted drugs are expected to remain resilient, but the next phase of market deepening will be driven not by conceptual innovation alone, but by system-level solutions capable of balancing molecular diagnostics, therapeutic benefit, accessibility, and commercial reproducibility.
LPI (LP Information)' newest research report, the ?Oncogene-Targeted Drugs Industry Forecast? looks at past sales and reviews total world Oncogene-Targeted Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Oncogene-Targeted Drugs sales for 2026 through 2032. With Oncogene-Targeted Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncogene-Targeted Drugs industry.
This Insight Report provides a comprehensive analysis of the global Oncogene-Targeted Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oncogene-Targeted Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Oncogene-Targeted Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncogene-Targeted Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncogene-Targeted Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncogene-Targeted Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Axitinib (Inlyta)
- Ponatinib (Iclusig)
- Imatinib (Gleevec)
- Sunitinib (Sutent)
- Pazopanib (Votrient)
- Dabrafenib (Tafinlar)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
- Cabozantinib (Cabometyx and Cometriq)
- Sorafenib (Nexavar)
- Chemical Synthesis Product
- Semi-Synthetic Product
- Recombinant Expression Product
- Cell-Culture Derived Product
- Enzymatic Synthesis Product
- Oligonucleotide Solid-Phase Synthesis Product
- Conjugation Process Product
- Bottle Presentation
- Blister Presentation
- Vial Presentation
- Ampoule Presentation
- Prefilled Syringe Presentation
- Cartridge Presentation
- Infusion Bag Presentation
- Clinic
- Hospital
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Johnson & Johnson
- Roche
- Pfizer
- AstraZeneca
- Eli Lilly
- Novartis
- Bristol Myers Squibb
- Bayer
- Takeda
- Amgen
- Boehringer Ingelheim
- Daiichi Sankyo
- Hengrui
- Hansoh
- Betta
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oncogene-Targeted Drugs Market Size (2021-2032)
2.1.2 Oncogene-Targeted Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oncogene-Targeted Drugs by Country/Region (2021, 2025 & 2032)
2.2 Oncogene-Targeted Drugs Segment by Type
2.2.1 Axitinib (Inlyta)
2.2.2 Ponatinib (Iclusig)
2.2.3 Imatinib (Gleevec)
2.2.4 Sunitinib (Sutent)
2.2.5 Pazopanib (Votrient)
2.2.6 Dabrafenib (Tafinlar)
2.2.7 Vandetanib (Caprelsa)
2.2.8 Vemurafenib (Zelboraf)
2.2.9 Cabozantinib (Cabometyx and Cometriq)
2.2.10 Oncogene-Targeted Drugs Market Size by Type
2.2.10.1 Oncogene-Targeted Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.10.2 Global Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
2.3 Oncogene-Targeted Drugs Segment by Manufacturing Process
2.3.1 Chemical Synthesis Product
2.3.2 Semi-Synthetic Product
2.3.3 Recombinant Expression Product
2.3.4 Cell-Culture Derived Product
2.3.5 Enzymatic Synthesis Product
2.3.6 Oligonucleotide Solid-Phase Synthesis Product
2.3.7 Conjugation Process Product
2.3.8 Oncogene-Targeted Drugs Market Size by Manufacturing Process
2.3.8.1 Oncogene-Targeted Drugs Market Size CAGR by Manufacturing Process (2021 VS 2025 VS 2032)
2.3.8.2 Global Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2021-2026)
2.4 Oncogene-Targeted Drugs Segment by Drug-Delivery Presentation
2.4.1 Bottle Presentation
2.4.2 Blister Presentation
2.4.3 Vial Presentation
2.4.4 Ampoule Presentation
2.4.5 Prefilled Syringe Presentation
2.4.6 Cartridge Presentation
2.4.7 Infusion Bag Presentation
2.4.8 Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation
2.4.8.1 Oncogene-Targeted Drugs Market Size CAGR by Drug-Delivery Presentation (2021 VS 2025 VS 2032)
2.4.8.2 Global Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2021-2026)
2.5 Oncogene-Targeted Drugs Segment by Application
2.5.1 Clinic
2.5.2 Hospital
2.5.3 Others
2.5.4 Oncogene-Targeted Drugs Market Size by Application
2.5.4.1 Oncogene-Targeted Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
3 ONCOGENE-TARGETED DRUGS MARKET SIZE BY PLAYER
3.1 Oncogene-Targeted Drugs Market Size Market Share by Player
3.1.1 Global Oncogene-Targeted Drugs Revenue by Player (2021-2026)
3.1.2 Global Oncogene-Targeted Drugs Revenue Market Share by Player (2021-2026)
3.2 Global Oncogene-Targeted Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ONCOGENE-TARGETED DRUGS BY REGION
4.1 Oncogene-Targeted Drugs Market Size by Region (2021-2026)
4.2 Global Oncogene-Targeted Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oncogene-Targeted Drugs Market Size Growth (2021-2026)
4.4 APAC Oncogene-Targeted Drugs Market Size Growth (2021-2026)
4.5 Europe Oncogene-Targeted Drugs Market Size Growth (2021-2026)
4.6 Middle East & Africa Oncogene-Targeted Drugs Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oncogene-Targeted Drugs Market Size by Country (2021-2026)
5.2 Americas Oncogene-Targeted Drugs Market Size by Type (2021-2026)
5.3 Americas Oncogene-Targeted Drugs Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oncogene-Targeted Drugs Market Size by Region (2021-2026)
6.2 APAC Oncogene-Targeted Drugs Market Size by Type (2021-2026)
6.3 APAC Oncogene-Targeted Drugs Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oncogene-Targeted Drugs Market Size by Country (2021-2026)
7.2 Europe Oncogene-Targeted Drugs Market Size by Type (2021-2026)
7.3 Europe Oncogene-Targeted Drugs Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oncogene-Targeted Drugs by Region (2021-2026)
8.2 Middle East & Africa Oncogene-Targeted Drugs Market Size by Type (2021-2026)
8.3 Middle East & Africa Oncogene-Targeted Drugs Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ONCOGENE-TARGETED DRUGS MARKET FORECAST
10.1 Global Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.1.1 Global Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.1.2 Americas Oncogene-Targeted Drugs Forecast
10.1.3 APAC Oncogene-Targeted Drugs Forecast
10.1.4 Europe Oncogene-Targeted Drugs Forecast
10.1.5 Middle East & Africa Oncogene-Targeted Drugs Forecast
10.2 Americas Oncogene-Targeted Drugs Forecast by Country (2027-2032)
10.2.1 United States Market Oncogene-Targeted Drugs Forecast
10.2.2 Canada Market Oncogene-Targeted Drugs Forecast
10.2.3 Mexico Market Oncogene-Targeted Drugs Forecast
10.2.4 Brazil Market Oncogene-Targeted Drugs Forecast
10.3 APAC Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.3.1 China Oncogene-Targeted Drugs Market Forecast
10.3.2 Japan Market Oncogene-Targeted Drugs Forecast
10.3.3 Korea Market Oncogene-Targeted Drugs Forecast
10.3.4 Southeast Asia Market Oncogene-Targeted Drugs Forecast
10.3.5 India Market Oncogene-Targeted Drugs Forecast
10.3.6 Australia Market Oncogene-Targeted Drugs Forecast
10.4 Europe Oncogene-Targeted Drugs Forecast by Country (2027-2032)
10.4.1 Germany Market Oncogene-Targeted Drugs Forecast
10.4.2 France Market Oncogene-Targeted Drugs Forecast
10.4.3 UK Market Oncogene-Targeted Drugs Forecast
10.4.4 Italy Market Oncogene-Targeted Drugs Forecast
10.4.5 Russia Market Oncogene-Targeted Drugs Forecast
10.5 Middle East & Africa Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.5.1 Egypt Market Oncogene-Targeted Drugs Forecast
10.5.2 South Africa Market Oncogene-Targeted Drugs Forecast
10.5.3 Israel Market Oncogene-Targeted Drugs Forecast
10.5.4 Turkey Market Oncogene-Targeted Drugs Forecast
10.6 Global Oncogene-Targeted Drugs Forecast by Type (2027-2032)
10.7 Global Oncogene-Targeted Drugs Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oncogene-Targeted Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Oncogene-Targeted Drugs Product Offered
11.1.3 Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Oncogene-Targeted Drugs Product Offered
11.2.3 Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Oncogene-Targeted Drugs Product Offered
11.3.3 Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Oncogene-Targeted Drugs Product Offered
11.4.3 AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Oncogene-Targeted Drugs Product Offered
11.5.3 Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Eli Lilly Main Business Overview
11.5.5 Eli Lilly Latest Developments
11.6 Novartis
11.6.1 Novartis Company Information
11.6.2 Novartis Oncogene-Targeted Drugs Product Offered
11.6.3 Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Novartis Main Business Overview
11.6.5 Novartis Latest Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Information
11.7.2 Bristol Myers Squibb Oncogene-Targeted Drugs Product Offered
11.7.3 Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bristol Myers Squibb Main Business Overview
11.7.5 Bristol Myers Squibb Latest Developments
11.8 Bayer
11.8.1 Bayer Company Information
11.8.2 Bayer Oncogene-Targeted Drugs Product Offered
11.8.3 Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Bayer Main Business Overview
11.8.5 Bayer Latest Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Oncogene-Targeted Drugs Product Offered
11.9.3 Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Takeda Main Business Overview
11.9.5 Takeda Latest Developments
11.10 Amgen
11.10.1 Amgen Company Information
11.10.2 Amgen Oncogene-Targeted Drugs Product Offered
11.10.3 Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Amgen Main Business Overview
11.10.5 Amgen Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Oncogene-Targeted Drugs Product Offered
11.11.3 Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Daiichi Sankyo
11.12.1 Daiichi Sankyo Company Information
11.12.2 Daiichi Sankyo Oncogene-Targeted Drugs Product Offered
11.12.3 Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Daiichi Sankyo Main Business Overview
11.12.5 Daiichi Sankyo Latest Developments
11.13 Hengrui
11.13.1 Hengrui Company Information
11.13.2 Hengrui Oncogene-Targeted Drugs Product Offered
11.13.3 Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Hengrui Main Business Overview
11.13.5 Hengrui Latest Developments
11.14 Hansoh
11.14.1 Hansoh Company Information
11.14.2 Hansoh Oncogene-Targeted Drugs Product Offered
11.14.3 Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Hansoh Main Business Overview
11.14.5 Hansoh Latest Developments
11.15 Betta
11.15.1 Betta Company Information
11.15.2 Betta Oncogene-Targeted Drugs Product Offered
11.15.3 Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Betta Main Business Overview
11.15.5 Betta Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oncogene-Targeted Drugs Market Size (2021-2032)
2.1.2 Oncogene-Targeted Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Oncogene-Targeted Drugs by Country/Region (2021, 2025 & 2032)
2.2 Oncogene-Targeted Drugs Segment by Type
2.2.1 Axitinib (Inlyta)
2.2.2 Ponatinib (Iclusig)
2.2.3 Imatinib (Gleevec)
2.2.4 Sunitinib (Sutent)
2.2.5 Pazopanib (Votrient)
2.2.6 Dabrafenib (Tafinlar)
2.2.7 Vandetanib (Caprelsa)
2.2.8 Vemurafenib (Zelboraf)
2.2.9 Cabozantinib (Cabometyx and Cometriq)
2.2.10 Oncogene-Targeted Drugs Market Size by Type
2.2.10.1 Oncogene-Targeted Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.10.2 Global Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
2.3 Oncogene-Targeted Drugs Segment by Manufacturing Process
2.3.1 Chemical Synthesis Product
2.3.2 Semi-Synthetic Product
2.3.3 Recombinant Expression Product
2.3.4 Cell-Culture Derived Product
2.3.5 Enzymatic Synthesis Product
2.3.6 Oligonucleotide Solid-Phase Synthesis Product
2.3.7 Conjugation Process Product
2.3.8 Oncogene-Targeted Drugs Market Size by Manufacturing Process
2.3.8.1 Oncogene-Targeted Drugs Market Size CAGR by Manufacturing Process (2021 VS 2025 VS 2032)
2.3.8.2 Global Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2021-2026)
2.4 Oncogene-Targeted Drugs Segment by Drug-Delivery Presentation
2.4.1 Bottle Presentation
2.4.2 Blister Presentation
2.4.3 Vial Presentation
2.4.4 Ampoule Presentation
2.4.5 Prefilled Syringe Presentation
2.4.6 Cartridge Presentation
2.4.7 Infusion Bag Presentation
2.4.8 Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation
2.4.8.1 Oncogene-Targeted Drugs Market Size CAGR by Drug-Delivery Presentation (2021 VS 2025 VS 2032)
2.4.8.2 Global Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2021-2026)
2.5 Oncogene-Targeted Drugs Segment by Application
2.5.1 Clinic
2.5.2 Hospital
2.5.3 Others
2.5.4 Oncogene-Targeted Drugs Market Size by Application
2.5.4.1 Oncogene-Targeted Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
3 ONCOGENE-TARGETED DRUGS MARKET SIZE BY PLAYER
3.1 Oncogene-Targeted Drugs Market Size Market Share by Player
3.1.1 Global Oncogene-Targeted Drugs Revenue by Player (2021-2026)
3.1.2 Global Oncogene-Targeted Drugs Revenue Market Share by Player (2021-2026)
3.2 Global Oncogene-Targeted Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ONCOGENE-TARGETED DRUGS BY REGION
4.1 Oncogene-Targeted Drugs Market Size by Region (2021-2026)
4.2 Global Oncogene-Targeted Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oncogene-Targeted Drugs Market Size Growth (2021-2026)
4.4 APAC Oncogene-Targeted Drugs Market Size Growth (2021-2026)
4.5 Europe Oncogene-Targeted Drugs Market Size Growth (2021-2026)
4.6 Middle East & Africa Oncogene-Targeted Drugs Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Oncogene-Targeted Drugs Market Size by Country (2021-2026)
5.2 Americas Oncogene-Targeted Drugs Market Size by Type (2021-2026)
5.3 Americas Oncogene-Targeted Drugs Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oncogene-Targeted Drugs Market Size by Region (2021-2026)
6.2 APAC Oncogene-Targeted Drugs Market Size by Type (2021-2026)
6.3 APAC Oncogene-Targeted Drugs Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Oncogene-Targeted Drugs Market Size by Country (2021-2026)
7.2 Europe Oncogene-Targeted Drugs Market Size by Type (2021-2026)
7.3 Europe Oncogene-Targeted Drugs Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oncogene-Targeted Drugs by Region (2021-2026)
8.2 Middle East & Africa Oncogene-Targeted Drugs Market Size by Type (2021-2026)
8.3 Middle East & Africa Oncogene-Targeted Drugs Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ONCOGENE-TARGETED DRUGS MARKET FORECAST
10.1 Global Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.1.1 Global Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.1.2 Americas Oncogene-Targeted Drugs Forecast
10.1.3 APAC Oncogene-Targeted Drugs Forecast
10.1.4 Europe Oncogene-Targeted Drugs Forecast
10.1.5 Middle East & Africa Oncogene-Targeted Drugs Forecast
10.2 Americas Oncogene-Targeted Drugs Forecast by Country (2027-2032)
10.2.1 United States Market Oncogene-Targeted Drugs Forecast
10.2.2 Canada Market Oncogene-Targeted Drugs Forecast
10.2.3 Mexico Market Oncogene-Targeted Drugs Forecast
10.2.4 Brazil Market Oncogene-Targeted Drugs Forecast
10.3 APAC Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.3.1 China Oncogene-Targeted Drugs Market Forecast
10.3.2 Japan Market Oncogene-Targeted Drugs Forecast
10.3.3 Korea Market Oncogene-Targeted Drugs Forecast
10.3.4 Southeast Asia Market Oncogene-Targeted Drugs Forecast
10.3.5 India Market Oncogene-Targeted Drugs Forecast
10.3.6 Australia Market Oncogene-Targeted Drugs Forecast
10.4 Europe Oncogene-Targeted Drugs Forecast by Country (2027-2032)
10.4.1 Germany Market Oncogene-Targeted Drugs Forecast
10.4.2 France Market Oncogene-Targeted Drugs Forecast
10.4.3 UK Market Oncogene-Targeted Drugs Forecast
10.4.4 Italy Market Oncogene-Targeted Drugs Forecast
10.4.5 Russia Market Oncogene-Targeted Drugs Forecast
10.5 Middle East & Africa Oncogene-Targeted Drugs Forecast by Region (2027-2032)
10.5.1 Egypt Market Oncogene-Targeted Drugs Forecast
10.5.2 South Africa Market Oncogene-Targeted Drugs Forecast
10.5.3 Israel Market Oncogene-Targeted Drugs Forecast
10.5.4 Turkey Market Oncogene-Targeted Drugs Forecast
10.6 Global Oncogene-Targeted Drugs Forecast by Type (2027-2032)
10.7 Global Oncogene-Targeted Drugs Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Oncogene-Targeted Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Oncogene-Targeted Drugs Product Offered
11.1.3 Johnson & Johnson Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Oncogene-Targeted Drugs Product Offered
11.2.3 Roche Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Oncogene-Targeted Drugs Product Offered
11.3.3 Pfizer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Oncogene-Targeted Drugs Product Offered
11.4.3 AstraZeneca Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Oncogene-Targeted Drugs Product Offered
11.5.3 Eli Lilly Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Eli Lilly Main Business Overview
11.5.5 Eli Lilly Latest Developments
11.6 Novartis
11.6.1 Novartis Company Information
11.6.2 Novartis Oncogene-Targeted Drugs Product Offered
11.6.3 Novartis Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Novartis Main Business Overview
11.6.5 Novartis Latest Developments
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Information
11.7.2 Bristol Myers Squibb Oncogene-Targeted Drugs Product Offered
11.7.3 Bristol Myers Squibb Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bristol Myers Squibb Main Business Overview
11.7.5 Bristol Myers Squibb Latest Developments
11.8 Bayer
11.8.1 Bayer Company Information
11.8.2 Bayer Oncogene-Targeted Drugs Product Offered
11.8.3 Bayer Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Bayer Main Business Overview
11.8.5 Bayer Latest Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Oncogene-Targeted Drugs Product Offered
11.9.3 Takeda Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Takeda Main Business Overview
11.9.5 Takeda Latest Developments
11.10 Amgen
11.10.1 Amgen Company Information
11.10.2 Amgen Oncogene-Targeted Drugs Product Offered
11.10.3 Amgen Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Amgen Main Business Overview
11.10.5 Amgen Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Oncogene-Targeted Drugs Product Offered
11.11.3 Boehringer Ingelheim Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Daiichi Sankyo
11.12.1 Daiichi Sankyo Company Information
11.12.2 Daiichi Sankyo Oncogene-Targeted Drugs Product Offered
11.12.3 Daiichi Sankyo Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Daiichi Sankyo Main Business Overview
11.12.5 Daiichi Sankyo Latest Developments
11.13 Hengrui
11.13.1 Hengrui Company Information
11.13.2 Hengrui Oncogene-Targeted Drugs Product Offered
11.13.3 Hengrui Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Hengrui Main Business Overview
11.13.5 Hengrui Latest Developments
11.14 Hansoh
11.14.1 Hansoh Company Information
11.14.2 Hansoh Oncogene-Targeted Drugs Product Offered
11.14.3 Hansoh Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Hansoh Main Business Overview
11.14.5 Hansoh Latest Developments
11.15 Betta
11.15.1 Betta Company Information
11.15.2 Betta Oncogene-Targeted Drugs Product Offered
11.15.3 Betta Oncogene-Targeted Drugs Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Betta Main Business Overview
11.15.5 Betta Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oncogene-Targeted Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oncogene-Targeted Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Axitinib (Inlyta)
Table 4. Major Players of Ponatinib (Iclusig)
Table 5. Major Players of Imatinib (Gleevec)
Table 6. Major Players of Sunitinib (Sutent)
Table 7. Major Players of Pazopanib (Votrient)
Table 8. Major Players of Dabrafenib (Tafinlar)
Table 9. Major Players of Vandetanib (Caprelsa)
Table 10. Major Players of Vemurafenib (Zelboraf)
Table 11. Major Players of Cabozantinib (Cabometyx and Cometriq)
Table 12. Oncogene-Targeted Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 14. Global Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Table 15. Major Players of Chemical Synthesis Product
Table 16. Major Players of Semi-Synthetic Product
Table 17. Major Players of Recombinant Expression Product
Table 18. Major Players of Cell-Culture Derived Product
Table 19. Major Players of Enzymatic Synthesis Product
Table 20. Major Players of Oligonucleotide Solid-Phase Synthesis Product
Table 21. Major Players of Conjugation Process Product
Table 22. Oncogene-Targeted Drugs Market Size CAGR by Manufacturing Process (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Oncogene-Targeted Drugs Market Size by Manufacturing Process (2021-2026) & ($ millions)
Table 24. Global Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2021-2026)
Table 25. Major Players of Bottle Presentation
Table 26. Major Players of Blister Presentation
Table 27. Major Players of Vial Presentation
Table 28. Major Players of Ampoule Presentation
Table 29. Major Players of Prefilled Syringe Presentation
Table 30. Major Players of Cartridge Presentation
Table 31. Major Players of Infusion Bag Presentation
Table 32. Oncogene-Targeted Drugs Market Size CAGR by Drug-Delivery Presentation (2021 VS 2025 VS 2032) & ($ millions)
Table 33. Global Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2021-2026) & ($ millions)
Table 34. Global Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2021-2026)
Table 35. Oncogene-Targeted Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 36. Global Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 37. Global Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Table 38. Global Oncogene-Targeted Drugs Revenue by Player (2021-2026) & ($ millions)
Table 39. Global Oncogene-Targeted Drugs Revenue Market Share by Player (2021-2026)
Table 40. Oncogene-Targeted Drugs Key Players Head office and Products Offered
Table 41. Oncogene-Targeted Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 42. New Products and Potential Entrants
Table 43. Mergers & Acquisitions, Expansion
Table 44. Global Oncogene-Targeted Drugs Market Size by Region (2021-2026) & ($ millions)
Table 45. Global Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Table 46. Global Oncogene-Targeted Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Oncogene-Targeted Drugs Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Oncogene-Targeted Drugs Market Size by Country (2021-2026) & ($ millions)
Table 49. Americas Oncogene-Targeted Drugs Market Size Market Share by Country (2021-2026)
Table 50. Americas Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 51. Americas Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Table 52. Americas Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 53. Americas Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Table 54. APAC Oncogene-Targeted Drugs Market Size by Region (2021-2026) & ($ millions)
Table 55. APAC Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Table 56. APAC Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 57. APAC Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 58. Europe Oncogene-Targeted Drugs Market Size by Country (2021-2026) & ($ millions)
Table 59. Europe Oncogene-Targeted Drugs Market Size Market Share by Country (2021-2026)
Table 60. Europe Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 61. Europe Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 62. Middle East & Africa Oncogene-Targeted Drugs Market Size by Region (2021-2026) & ($ millions)
Table 63. Middle East & Africa Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 64. Middle East & Africa Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 65. Key Market Drivers & Growth Opportunities of Oncogene-Targeted Drugs
Table 66. Key Market Challenges & Risks of Oncogene-Targeted Drugs
Table 67. Key Industry Trends of Oncogene-Targeted Drugs
Table 68. Global Oncogene-Targeted Drugs Market Size Forecast by Region (2027-2032) & ($ millions)
Table 69. Global Oncogene-Targeted Drugs Market Size Market Share Forecast by Region (2027-2032)
Table 70. Global Oncogene-Targeted Drugs Market Size Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Oncogene-Targeted Drugs Market Size Forecast by Application (2027-2032) & ($ millions)
Table 72. Johnson & Johnson Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 73. Johnson & Johnson Oncogene-Targeted Drugs Product Offered
Table 74. Johnson & Johnson Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Johnson & Johnson Main Business
Table 76. Johnson & Johnson Latest Developments
Table 77. Roche Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 78. Roche Oncogene-Targeted Drugs Product Offered
Table 79. Roche Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Roche Main Business
Table 81. Roche Latest Developments
Table 82. Pfizer Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 83. Pfizer Oncogene-Targeted Drugs Product Offered
Table 84. Pfizer Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. AstraZeneca Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 88. AstraZeneca Oncogene-Targeted Drugs Product Offered
Table 89. AstraZeneca Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. AstraZeneca Main Business
Table 91. AstraZeneca Latest Developments
Table 92. Eli Lilly Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 93. Eli Lilly Oncogene-Targeted Drugs Product Offered
Table 94. Eli Lilly Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Eli Lilly Main Business
Table 96. Eli Lilly Latest Developments
Table 97. Novartis Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 98. Novartis Oncogene-Targeted Drugs Product Offered
Table 99. Novartis Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Bristol Myers Squibb Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 103. Bristol Myers Squibb Oncogene-Targeted Drugs Product Offered
Table 104. Bristol Myers Squibb Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Bristol Myers Squibb Main Business
Table 106. Bristol Myers Squibb Latest Developments
Table 107. Bayer Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 108. Bayer Oncogene-Targeted Drugs Product Offered
Table 109. Bayer Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Bayer Main Business
Table 111. Bayer Latest Developments
Table 112. Takeda Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 113. Takeda Oncogene-Targeted Drugs Product Offered
Table 114. Takeda Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. Takeda Main Business
Table 116. Takeda Latest Developments
Table 117. Amgen Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 118. Amgen Oncogene-Targeted Drugs Product Offered
Table 119. Amgen Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. Amgen Main Business
Table 121. Amgen Latest Developments
Table 122. Boehringer Ingelheim Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 123. Boehringer Ingelheim Oncogene-Targeted Drugs Product Offered
Table 124. Boehringer Ingelheim Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Boehringer Ingelheim Main Business
Table 126. Boehringer Ingelheim Latest Developments
Table 127. Daiichi Sankyo Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 128. Daiichi Sankyo Oncogene-Targeted Drugs Product Offered
Table 129. Daiichi Sankyo Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. Daiichi Sankyo Main Business
Table 131. Daiichi Sankyo Latest Developments
Table 132. Hengrui Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 133. Hengrui Oncogene-Targeted Drugs Product Offered
Table 134. Hengrui Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Hengrui Main Business
Table 136. Hengrui Latest Developments
Table 137. Hansoh Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 138. Hansoh Oncogene-Targeted Drugs Product Offered
Table 139. Hansoh Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Hansoh Main Business
Table 141. Hansoh Latest Developments
Table 142. Betta Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 143. Betta Oncogene-Targeted Drugs Product Offered
Table 144. Betta Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 145. Betta Main Business
Table 146. Betta Latest Developments
Table 1. Oncogene-Targeted Drugs Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Oncogene-Targeted Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Axitinib (Inlyta)
Table 4. Major Players of Ponatinib (Iclusig)
Table 5. Major Players of Imatinib (Gleevec)
Table 6. Major Players of Sunitinib (Sutent)
Table 7. Major Players of Pazopanib (Votrient)
Table 8. Major Players of Dabrafenib (Tafinlar)
Table 9. Major Players of Vandetanib (Caprelsa)
Table 10. Major Players of Vemurafenib (Zelboraf)
Table 11. Major Players of Cabozantinib (Cabometyx and Cometriq)
Table 12. Oncogene-Targeted Drugs Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 14. Global Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Table 15. Major Players of Chemical Synthesis Product
Table 16. Major Players of Semi-Synthetic Product
Table 17. Major Players of Recombinant Expression Product
Table 18. Major Players of Cell-Culture Derived Product
Table 19. Major Players of Enzymatic Synthesis Product
Table 20. Major Players of Oligonucleotide Solid-Phase Synthesis Product
Table 21. Major Players of Conjugation Process Product
Table 22. Oncogene-Targeted Drugs Market Size CAGR by Manufacturing Process (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global Oncogene-Targeted Drugs Market Size by Manufacturing Process (2021-2026) & ($ millions)
Table 24. Global Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process (2021-2026)
Table 25. Major Players of Bottle Presentation
Table 26. Major Players of Blister Presentation
Table 27. Major Players of Vial Presentation
Table 28. Major Players of Ampoule Presentation
Table 29. Major Players of Prefilled Syringe Presentation
Table 30. Major Players of Cartridge Presentation
Table 31. Major Players of Infusion Bag Presentation
Table 32. Oncogene-Targeted Drugs Market Size CAGR by Drug-Delivery Presentation (2021 VS 2025 VS 2032) & ($ millions)
Table 33. Global Oncogene-Targeted Drugs Market Size by Drug-Delivery Presentation (2021-2026) & ($ millions)
Table 34. Global Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation (2021-2026)
Table 35. Oncogene-Targeted Drugs Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 36. Global Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 37. Global Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Table 38. Global Oncogene-Targeted Drugs Revenue by Player (2021-2026) & ($ millions)
Table 39. Global Oncogene-Targeted Drugs Revenue Market Share by Player (2021-2026)
Table 40. Oncogene-Targeted Drugs Key Players Head office and Products Offered
Table 41. Oncogene-Targeted Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 42. New Products and Potential Entrants
Table 43. Mergers & Acquisitions, Expansion
Table 44. Global Oncogene-Targeted Drugs Market Size by Region (2021-2026) & ($ millions)
Table 45. Global Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Table 46. Global Oncogene-Targeted Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Oncogene-Targeted Drugs Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Oncogene-Targeted Drugs Market Size by Country (2021-2026) & ($ millions)
Table 49. Americas Oncogene-Targeted Drugs Market Size Market Share by Country (2021-2026)
Table 50. Americas Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 51. Americas Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Table 52. Americas Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 53. Americas Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Table 54. APAC Oncogene-Targeted Drugs Market Size by Region (2021-2026) & ($ millions)
Table 55. APAC Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Table 56. APAC Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 57. APAC Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 58. Europe Oncogene-Targeted Drugs Market Size by Country (2021-2026) & ($ millions)
Table 59. Europe Oncogene-Targeted Drugs Market Size Market Share by Country (2021-2026)
Table 60. Europe Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 61. Europe Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 62. Middle East & Africa Oncogene-Targeted Drugs Market Size by Region (2021-2026) & ($ millions)
Table 63. Middle East & Africa Oncogene-Targeted Drugs Market Size by Type (2021-2026) & ($ millions)
Table 64. Middle East & Africa Oncogene-Targeted Drugs Market Size by Application (2021-2026) & ($ millions)
Table 65. Key Market Drivers & Growth Opportunities of Oncogene-Targeted Drugs
Table 66. Key Market Challenges & Risks of Oncogene-Targeted Drugs
Table 67. Key Industry Trends of Oncogene-Targeted Drugs
Table 68. Global Oncogene-Targeted Drugs Market Size Forecast by Region (2027-2032) & ($ millions)
Table 69. Global Oncogene-Targeted Drugs Market Size Market Share Forecast by Region (2027-2032)
Table 70. Global Oncogene-Targeted Drugs Market Size Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Oncogene-Targeted Drugs Market Size Forecast by Application (2027-2032) & ($ millions)
Table 72. Johnson & Johnson Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 73. Johnson & Johnson Oncogene-Targeted Drugs Product Offered
Table 74. Johnson & Johnson Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Johnson & Johnson Main Business
Table 76. Johnson & Johnson Latest Developments
Table 77. Roche Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 78. Roche Oncogene-Targeted Drugs Product Offered
Table 79. Roche Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. Roche Main Business
Table 81. Roche Latest Developments
Table 82. Pfizer Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 83. Pfizer Oncogene-Targeted Drugs Product Offered
Table 84. Pfizer Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Pfizer Main Business
Table 86. Pfizer Latest Developments
Table 87. AstraZeneca Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 88. AstraZeneca Oncogene-Targeted Drugs Product Offered
Table 89. AstraZeneca Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. AstraZeneca Main Business
Table 91. AstraZeneca Latest Developments
Table 92. Eli Lilly Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 93. Eli Lilly Oncogene-Targeted Drugs Product Offered
Table 94. Eli Lilly Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Eli Lilly Main Business
Table 96. Eli Lilly Latest Developments
Table 97. Novartis Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 98. Novartis Oncogene-Targeted Drugs Product Offered
Table 99. Novartis Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Novartis Main Business
Table 101. Novartis Latest Developments
Table 102. Bristol Myers Squibb Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 103. Bristol Myers Squibb Oncogene-Targeted Drugs Product Offered
Table 104. Bristol Myers Squibb Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Bristol Myers Squibb Main Business
Table 106. Bristol Myers Squibb Latest Developments
Table 107. Bayer Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 108. Bayer Oncogene-Targeted Drugs Product Offered
Table 109. Bayer Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Bayer Main Business
Table 111. Bayer Latest Developments
Table 112. Takeda Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 113. Takeda Oncogene-Targeted Drugs Product Offered
Table 114. Takeda Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. Takeda Main Business
Table 116. Takeda Latest Developments
Table 117. Amgen Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 118. Amgen Oncogene-Targeted Drugs Product Offered
Table 119. Amgen Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. Amgen Main Business
Table 121. Amgen Latest Developments
Table 122. Boehringer Ingelheim Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 123. Boehringer Ingelheim Oncogene-Targeted Drugs Product Offered
Table 124. Boehringer Ingelheim Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Boehringer Ingelheim Main Business
Table 126. Boehringer Ingelheim Latest Developments
Table 127. Daiichi Sankyo Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 128. Daiichi Sankyo Oncogene-Targeted Drugs Product Offered
Table 129. Daiichi Sankyo Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. Daiichi Sankyo Main Business
Table 131. Daiichi Sankyo Latest Developments
Table 132. Hengrui Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 133. Hengrui Oncogene-Targeted Drugs Product Offered
Table 134. Hengrui Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Hengrui Main Business
Table 136. Hengrui Latest Developments
Table 137. Hansoh Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 138. Hansoh Oncogene-Targeted Drugs Product Offered
Table 139. Hansoh Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 140. Hansoh Main Business
Table 141. Hansoh Latest Developments
Table 142. Betta Details, Company Type, Oncogene-Targeted Drugs Area Served and Its Competitors
Table 143. Betta Oncogene-Targeted Drugs Product Offered
Table 144. Betta Oncogene-Targeted Drugs Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 145. Betta Main Business
Table 146. Betta Latest Developments
LIST OF FIGURES
Figure 1. Oncogene-Targeted Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oncogene-Targeted Drugs Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oncogene-Targeted Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oncogene-Targeted Drugs Sales Market Share by Country/Region (2025)
Figure 8. Oncogene-Targeted Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oncogene-Targeted Drugs Market Size Market Share by Type in 2025
Figure 10. Global Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process in 2025
Figure 11. Global Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation in 2025
Figure 12. Oncogene-Targeted Drugs in Clinic
Figure 13. Global Oncogene-Targeted Drugs Market: Clinic (2021-2026) & ($ millions)
Figure 14. Oncogene-Targeted Drugs in Hospital
Figure 15. Global Oncogene-Targeted Drugs Market: Hospital (2021-2026) & ($ millions)
Figure 16. Oncogene-Targeted Drugs in Others
Figure 17. Global Oncogene-Targeted Drugs Market: Others (2021-2026) & ($ millions)
Figure 18. Global Oncogene-Targeted Drugs Market Size Market Share by Application in 2025
Figure 19. Global Oncogene-Targeted Drugs Revenue Market Share by Player in 2025
Figure 20. Global Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Figure 21. Americas Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 22. APAC Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 23. Europe Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 25. Americas Oncogene-Targeted Drugs Value Market Share by Country in 2025
Figure 26. United States Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Oncogene-Targeted Drugs Market Size Market Share by Region in 2025
Figure 31. APAC Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Figure 32. APAC Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Figure 33. China Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 37. India Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Oncogene-Targeted Drugs Market Size Market Share by Country in 2025
Figure 40. Europe Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Figure 41. Europe Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Figure 42. Germany Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 43. France Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 56. APAC Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 57. Europe Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 59. United States Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 60. Canada Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 61. Mexico Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 62. Brazil Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 63. China Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 64. Japan Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 65. Korea Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 67. India Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 68. Australia Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 69. Germany Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 70. France Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 71. UK Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 72. Italy Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 73. Russia Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 74. Egypt Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 75. South Africa Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 76. Israel Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 77. Turkey Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 78. Global Oncogene-Targeted Drugs Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Oncogene-Targeted Drugs Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 1. Oncogene-Targeted Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Oncogene-Targeted Drugs Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Oncogene-Targeted Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Oncogene-Targeted Drugs Sales Market Share by Country/Region (2025)
Figure 8. Oncogene-Targeted Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Oncogene-Targeted Drugs Market Size Market Share by Type in 2025
Figure 10. Global Oncogene-Targeted Drugs Market Size Market Share by Manufacturing Process in 2025
Figure 11. Global Oncogene-Targeted Drugs Market Size Market Share by Drug-Delivery Presentation in 2025
Figure 12. Oncogene-Targeted Drugs in Clinic
Figure 13. Global Oncogene-Targeted Drugs Market: Clinic (2021-2026) & ($ millions)
Figure 14. Oncogene-Targeted Drugs in Hospital
Figure 15. Global Oncogene-Targeted Drugs Market: Hospital (2021-2026) & ($ millions)
Figure 16. Oncogene-Targeted Drugs in Others
Figure 17. Global Oncogene-Targeted Drugs Market: Others (2021-2026) & ($ millions)
Figure 18. Global Oncogene-Targeted Drugs Market Size Market Share by Application in 2025
Figure 19. Global Oncogene-Targeted Drugs Revenue Market Share by Player in 2025
Figure 20. Global Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Figure 21. Americas Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 22. APAC Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 23. Europe Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Oncogene-Targeted Drugs Market Size 2021-2026 ($ millions)
Figure 25. Americas Oncogene-Targeted Drugs Value Market Share by Country in 2025
Figure 26. United States Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Oncogene-Targeted Drugs Market Size Market Share by Region in 2025
Figure 31. APAC Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Figure 32. APAC Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Figure 33. China Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 37. India Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Oncogene-Targeted Drugs Market Size Market Share by Country in 2025
Figure 40. Europe Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Figure 41. Europe Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Figure 42. Germany Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 43. France Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Oncogene-Targeted Drugs Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Oncogene-Targeted Drugs Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Oncogene-Targeted Drugs Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Oncogene-Targeted Drugs Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 56. APAC Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 57. Europe Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 59. United States Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 60. Canada Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 61. Mexico Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 62. Brazil Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 63. China Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 64. Japan Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 65. Korea Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 67. India Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 68. Australia Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 69. Germany Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 70. France Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 71. UK Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 72. Italy Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 73. Russia Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 74. Egypt Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 75. South Africa Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 76. Israel Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 77. Turkey Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
Figure 78. Global Oncogene-Targeted Drugs Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Oncogene-Targeted Drugs Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Oncogene-Targeted Drugs Market Size 2027-2032 ($ millions)
